Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rich Brody"'
Autor:
Reetobrata Basu, Prateek Kulkarni, Deborah Swegan, Silvana Duran-Ortiz, Arshad Ahmad, Lydia J. Caggiano, Emily Davis, Christopher Walsh, Edward Brenya, Adeel Koshal, Rich Brody, Uday Sandbhor, Sebastian J. C. M. M. Neggers, John J. Kopchick
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 7438 (2024)
Chemotherapy treatment against pancreatic ductal adenocarcinoma (PDAC) is thwarted by tumoral activation of multiple therapy resistance pathways. The growth hormone (GH)–GH receptor (GHR) pair is a covert driver of multimodal therapy resistance in
Externí odkaz:
https://doaj.org/article/1a3f8bb5ee834aec859077d1d8d528f8
Autor:
John K. Cini, Susan Dexter, Darrel J. Rezac, Stephen J. McAndrew, Gael Hedou, Rich Brody, Rukiye-Nazan Eraslan, Richard T. Kenney, Pankaj Mohan
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundThe potential synergy between interleukin-12 (IL-12) and IL-15 holds promise for more effective solid tumor immunotherapy. Nevertheless, previous clinical trials involving therapeutic cytokines have encountered obstacles such as short pharm
Externí odkaz:
https://doaj.org/article/ec5b713791af4cd19df56d27a6cab5cc
Autor:
George H. Hinkle, Shankaran Kothandaraman, Alex Pokora, Keisha Milum, Michelle M. Carlton, Krishan Kumar, Haiming Ding, Stephen P. Povoski, Rich Brody, Edward W. Martin, Mitchell Phelps, Paul D. Davis, David Colcher, Michael F. Tweedle
The tumor-associated glycoprotein-72 (TAG-72) antigen is highly overexpressed in various human adenocarcinomas and anti-TAG-72 monoclonal antibodies, and fragments are therefore useful as pharmaceutical targeting vectors. In this study, we investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26a067850856c1210c99aabddd5bab0a
https://europepmc.org/articles/PMC4240220/
https://europepmc.org/articles/PMC4240220/
